New shot aims to stop stroke damage in its tracks

NCT ID NCT07301372

Recruiting now Disease control Sponsor: The Affiliated Hospital of Xuzhou Medical University Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding an injectable cholesterol-lowering drug (evolocumab) to standard stroke treatment can help prevent patients from getting worse in the first week after a stroke. It involves 132 adults who have just had an ischemic stroke caused by clogged arteries and received clot-busting medication. Researchers will compare those who get the extra drug injection to those who receive only standard medications, looking at whether it reduces early neurological decline and improves 90-day recovery.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE STROKE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Department of Neurology
RECRUITING

Xuzhou, Jiangsu, China

Contact

Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

ACUTE STROKE